Capromorelin

Capromorelin is an investigational medication developed by the Pfizer drug company. It functions as a growth hormone secretagogue and ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Initial studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) levels.

Additional recommended knowledge

Don't let static charges disrupt your weighing accuracy

Recognize and detect the effects of electrostatic charges on your balance

What is the Sensitivity of my Balance?

The drug is being considered for its therapeutic value in aging adults because elderly people have much lower levels of growth hormone -- and less lean muscle mass, which can result in weakness and frailty.

Patients who got the drug gained an average of 3 pounds (1.4 kg) in lean muscle mass after six months, and also were better able to walk a straight line -- a test of balance, strength and coordination. Some of the improvements were evident a year later.

Capromorelin, however, has not been approved by the FDA, and is not expected to be so any time soon. This is because the FDA does not consider aging a disease, and so requires extraordinary evidence of benefit and non-toxicity to approve a drug for use as an anti-aging agent.

Researchers

• Pfizer
• Merck
• University of Washington/VA Puget Sound Health Care System: Dr. George Merriam
• University of Poland: Dr. Agnieszka Baranowska-Bik

• Capromorelin Information